« Return to News | Clinical Intelligence

Durect reports Eladur phase II results in back pain

Tuesday, April 12, 2011 12:30 PM

Durect has released results from a phase II clinical trial in chronic low back pain for Eladur (Transdurr-Bupivacaine), Durect's investigational transdermal bupivacaine pain patch. This study was conducted by Durect's collaborator, King Pharmaceuticals, which is now owned by Pfizer. In this study of 263 patients suffering from chronic low back pain, the primary efficacy endpoint of demonstrating a positive treatment difference for the mean change in pain intensity scores from baseline to the mean of weeks 11 and 12 between Eladur as compared to placebo was not met.  Complete data analysis is ongoing.

Eladur is an investigational transdermal drug patch intended to deliver bupivacaine for up to three days from a single application.  Bupivacaine, the active agent in Eladur, is a potent, FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia.  Eladur demonstrated a positive efficacy trend in a phase IIa study for post-herpetic neuralgia (PHN).

"Demonstrating efficacy against placebo in a chronic low back pain trial is challenging for any topical locally-acting product," stated James E. Brown, DVM, president and CEO of Durect.  "We and Pfizer are continuing to analyze this most recent study and will work together to determine next steps."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.